Kamamoto Sae, Murayama Anju, Kusumi Eiji, Yoshida Makoto, Saito Hiroaki, Sawano Toyoaki, Yamashita Erika, Tanimoto Tetsuya, Ozaki Akihiko
Medical Governance Research Institute, Minato-ku, Tokyo, Japan.
Hamamatsu University School of Medicine, Hamamatsu city, Shizuoka, Japan.
Pediatr Blood Cancer. 2022 Oct;69(10):e29891. doi: 10.1002/pbc.29891. Epub 2022 Aug 10.
This cross-sectional study evaluated the magnitude of personal payments made by pharmaceutical companies to pediatric hematologist-oncologists (PHOs) board-certified by the Japanese Society of Pediatric Hematology/Oncology (JSPHO), using publicly disclosed data. Among all 307 PHOs, 215 (70.0%) PHOs received $916 703 personal payments from 54 pharmaceutical companies between 2016 and 2019 in total. Median four-year payments per PHO was $1440 (interquartile range, $523-$4015). Payments per PHO significantly increased during the study period, by 23.8% (95% confidence interval: 15.3%-32.8%, P < 0.001) annually. Furthermore, leading PHOs, including university professors, society board members, and clinical practice guideline authors, received far larger personal payments from the companies.
这项横断面研究利用公开披露的数据，评估了制药公司向日本小儿血液学/肿瘤学会（JSPHO）认证的小儿血液肿瘤学家（PHO）支付的个人报酬规模。在所有307名PHO中，215名（70.0%）PHO在2016年至2019年期间共从54家制药公司获得了916,703美元的个人报酬。每位PHO四年报酬的中位数为1440美元（四分位间距为523 - 4015美元）。在研究期间，每位PHO的报酬显著增加，每年增长23.8%（95%置信区间：15.3% - 32.8%，P < 0.001）。此外，包括大学教授、学会董事会成员和临床实践指南作者在内的主要PHO从公司获得的个人报酬要多得多。
